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Abstract Insulin stimulated protein kinase Ba (PKBa) more 
than 10-fold and decreased glycogen synthase kinase-3 (GSK3) 
activity by 50 ± 10% in skeletal muscle and adipocytes. 
Rapamycin did not prevent the activation of PKB, inhibition of 
GSK3 or stimulation of glycogen synthase up to 5 min. Thus 
rapamycin-insensitive pathways mediate the acute effect of 
insulin on glycogen synthase in the major insulin-responsive 
tissues. The small and very transient effects of EGF on 
phosphatidylinositol (3,4,5)P3 PKBa and GSK3 in adipocytes, 
compared to the strong and sustained effects of insulin, explains 
why EGF does not stimulate glucose uptake or glycogen 
synthesis in adipocytes. 
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1. Introduction 
Insulin triggers the dephosphorylation and activation of 
glycogen synthase within minutes in skeletal muscle and adi-
pose tissue, an important event in the stimulation of glycogen 
synthesis by this hormone. In skeletal muscle, most of the 
phosphate is released from a region of glycogen synthase 
that is phosphorylated in vitro by glycogen synthase kinase-
3 (GSK3) [1,2] and dephosphorylated by a glycogen-associ-
ated form of protein phosphatase-1 ( P P I . G M ) [3,4]. These 
findings suggest that insulin activates glycogen synthase by 
inhibiting GSK3 and/or activating P P I . G M , and there is evi-
dence that both of these mechanisms may operate in vivo. In 
skeletal muscle, insulin increases the phosphorylation of the 
glycogen-binding (GM) subunit at Ser-48, which should in-
crease the rate at which P P I . G M dephosphorylates glycogen 
synthase [5], while in several cell lines insulin has been shown 
to inhibit GSK3 [6,7] by inducing its phosphorylation at ser-
ine/threonine residues [7-9]. 
In rat L6 myotubes, a skeletal muscle cell line, the residues 
in GSK3 that become phosphorylated in response to insulin 
are Ser-21 in GSK3oc and Ser-9 in GSK3(3 [10], raising the 
question of which insulin-stimulated protein kinase phospho-
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rylates these sites in vivo. This problem is complex because 
three distinct insulin-stimulated protein kinases catalyse the 
phosphorylation of Ser-21 and Ser-9 in vitro, namely 
p70 S6 kinase [11,12], MAP kinase-activated protein kinase-
1 (MAPKAP-K1, also known as Rsk) [11,12] and protein 
kinase B (PKB, also known as c-Akt) [10]. In L6 myotubes 
[10] human myoblasts [13] or primary adipocytes [14], neither 
rapamycin (a drug which prevents the activation of p70 S6 
kinase) nor PD 98059 (which inhibits activation of the MAP 
kinase pathway and hence the activation of MAPKAP-K1 
[15]) have any effect on the inhibition of GSK3 by insulin. 
Moreover, the half-time for activation of p70 S6 kinase or 
MAPKAP-K1 by insulin (5-7 min) is much slower than the 
half-time for inhibition of GSK3 (2 min) [10,13]. Thus neither 
p70 S6 kinase nor MAPKAP-K1 are rate limiting for GSK3 
inhibition by insulin in L6 myotubes, human myoblasts or 
primary adipocytes. 
The activation of PKB by insulin, like the inhibition of 
GSK3, is unaffected by rapamycin and/or PD 98059 in L6 
myotubes [10] or human myoblasts [13], and several further 
pieces of evidence suggest that PKB may mediate the inhib-
ition of GSK3 in these cells. First, the half-time for activation 
of PKB (1 min) is consistent with it being an upstream acti-
vator of GSK3 [10]. Second, the activation of PKB by insulin, 
like the inhibition of GSK3, is prevented by inhibitors of 
phosphoinositide (PI) 3-kinase [10,15,16]. Third, GSK3 be-
comes inhibited when it is cotransfected with PKB in 293 cells 
(D. Alessi and P. Cohen, unpublished work). 
A role for MAPKAP-K1 in the activation of glycogen syn-
thase by insulin has been excluded by several findings. First, 
MAPKAP-K1[3 (Rsk-2) is not activated by insulin in the skel-
etal muscles of transgenic mice expressing a mutated insulin 
receptor, whereas the activation of glycogen synthase by in-
sulin is unimpaired [18]. Secondly, PD 98059 has no effect on 
the stimulation of glycogen synthase or glycogen synthesis by 
insulin in human myotubes [13] or primary adipocytes [19]. 
Thirdly, epidermal growth factor (EGF) induces a stronger 
activation of MAP kinase than insulin in adipocytes, but 
does not stimulate glycogen synthase or glycogen synthesis 
[20]. 
Although, rapamycin does not inhibit the acute activation 
of glycogen synthase by insulin in L6 myotubes [10], or pri-
mary adipocytes [20], and has little effect in human myoblasts 
[13], the insulin-induced stimulation of glycogen synthase in 
3T3-L1 adipocytes [21] and isolated rat hemidiaphragms [22] 
were reported to be inhibited by rapamycin. In addition, ra-
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pamycin was reported to strongly suppress the insulin induced 
stimulation of glycogen synthesis in human myoblasts when 
measured after a long time period (2 h) [13] These findings 
suggested that the signal transduction pathway utilised by 
insulin to activate glycogen synthase may vary with cell type 
and with the length of stimulation. They also raised the ques-
tion of whether, in some cells, p70 S6 kinase might mediate 
the inhibition of GSK3 by insulin and whether the activation 
of P K B might be prevented by rapamycin. Fo r these reasons, 
we have investigated the effect of rapamycin on the activation 
of PKB, the inhibition of GSK3 and the activation of glyco-
gen synthase in the major insulin-responsive tissues, namely 
skeletal muscle and primary adipocytes. Our results demon-
strate that rapamycin has no effect on the insulin-induced 
activation of P K B or the inhibition of G S K 3 in these tissues. 
Moreover, the activation of glycogen synthase induced by 
insulin in skeletal muscle is not affected by rapamycin after 
5 min, al though it is partially suppressed at later times. We 
conclude that rapamycin-insensitive pathways are largely re-
sponsible for mediating the acute inhibition of G S K 3 and 
activation of glycogen synthase in the major insulin-respon-
sive tissues. We also show that E G F does not mimic the effect 
of insulin on glycogen synthase in adipocytes because the 
activation of PI 3-kinase and PKB induced by this agonist 
are too small and transient for significant inhibition of GSK3 
to take place. 
2. Materials and methods 
2.1. Materials 
Rapamycin, a generous gift from Carol Germain (Warner-Lambert 
Co., Michigan, USA), was dissolved in dimethylsulphoxide (DMSO) 
at a concentration of 10 mM. Wortmannin was purchased from Sig-
ma Chemical Co. (Poole, UK), insulin from Novo-Nordisk (Bags-
vaerd, Denmark), sodium pentobarbitione (Sagatal) from May and 
Baker (Dagenham, UK) and epidermal growth factor from Boeh-
ringer (Lewes, UK). The 'complete' proteinase inhibitor cocktail 
was also purchased from Boehringer and used as recommended by 
the supplier. 
2.2. Insulin stimulation of rat skeletal muscle in vivo 
Male Wistar rats (200 g) were deprived of food overnight and 
anaesthetised by intraperitoneal injection with sodium pentobarbi-
tione (5 mg/100 g). Once fully anaesthetized one of the lower limbs 
was partially skinned on the medial aspect to expose the saphenous 
vein. Fifteen microlitres of DMSO or rapamycin in DMSO (10 mM) 
were diluted with 0.5 ml of 150 mM NaCl and injected into the 
saphenous vein 5 min prior to injection of propranolol (3.0 mg/kg) 
or propranolol plus insulin (1.0 U/kg). When 30 min time points were 
being analysed, an additional injection of rapamycin was made 15 min 
after the injection of insulin. At various times, muscle from the con-
tralateral leg was taken by freeze-clamping with Wollenberger Tongs 
which had been cooled to the temperature of liquid nitrogen. The 
frozen muscle was powdered finely under liquid nitrogen using a pes-
tle and mortar precooled in liquid nitrogen and stored at —80°C until 
required. Each 1 g of powdered muscle was homogenised at 4°C using 
a Polytron in 3.0 ml of 4.0 mM EDTA, 50 mM NaF, pH 8.0, con-
taining 1.0 mM sodium orthovanadate, 1.0 uM microcystin-LR, 0.1% 
(v/v) 2-mercaptoethanol and the proteinase inhibitor cocktail. The 
homogenate was centrifuged at 13000Xg for 10 min at 4°C and the 
supernatant removed and used immediately for enzyme assays or 
snap-frozen in liquid nitrogen and stored in 0.5 ml aliquots at 
—80°C until required 
2.3. Stimulation of rat adipocytes with insulin or EGF 
Epididymal fat pads from eight male Wistar rats (170-180 g) were 
placed in a plastic beaker and each 1 g of tissue incubated at 37°C 
with 3.0 ml of 120 mM NaCl, 10 mM NaHC0 3 , 30 mM HEPES, 1.2 
mM MgS04 , 4.7 mM KCl, 1.2 mM KH 2 P0 4 , 2.5 mM CaCl2, 40 mg/ 
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ml BSA, 1.0 mg/ml glucose and 0.2 uM adenosine, pH 7.4, and 3.0 mg 
of collagenase. The pads were finely chopped with scissors and incu-
bated for 1 h at 37°C on a rocking platform. The adipocytes were 
strained twice through a 0.5 mm2 plastic sieve, then washed 4 times at 
37°C with fresh buffer without collagenase, resuspended in 20 ml of 
buffer and incubated for 20 min at 37°C. Aliquots (1.0 ml) of adipo-
cyte suspension were then incubated for a further 20 min in a 37°C air 
incubator, before treatment for 10 min with DMSO carrier, rapamy-
cin (100 nM) or wortmannin (100 nM) and then stimulated for var-
ious times without or with EGF (200 ng/ml) or insulin (200 nM) on a 
low-speed shaking platform (ensuring adipocytes were in a uniform 
suspension) at 37°C. Stimulations were stopped by addition of 10 ul 
of 0.2 M EDTA, 5.0 ul of 0.2 M EGTA, pH 8.0, containing 10 ul of 
0.1 M sodium orthovanadate, pH 1.0, ul of 2-mercaptoethanol and 
0.5 ul of 2.0 mM microcystin-LR, immediately snap-frozen in liquid 
nitrogen and stored at — 80°C until required. Samples were then 
thawed, centrifuged at 13000Xg for 5 min at 4°C and the infrana-
tants transferred into fresh tubes, recentrifuged and the supernatants 
assayed for the enzymatic activities as described below. 
2.4. Immunoprecipitation and assay of protein kinases 
PKBa [10] GSK3 [8], p42 MAP kinase [8], MAPKAP-Kip [8] and 
p70 S6 kinase [23] were immunoprecipitated from skeletal muscle 
and adipocyte extracts as described previously. PKBa and MAP-
KAP-Kip were both assayed using Crosstide [10], GSK3 using phos-
pho-GS peptide-1 [8], p42 MAP kinase using myelin basic protein [24] 
and p70 S6 kinase using the specific peptide substrate 
KKRNRTLTV [25]. One unit of activity (U) was that amount which 
catalysed the phosphorylation of 1 nmol of substrate in 1 min. 
2.5. Other analytical procedures 
PI-(3,4,5)-trisphosphate was measured as described previously [26]. 
Glycogen synthase was assayed at pH 6.8 by measuring the incorpo-
ration of [14C]glucose (G) from uridine diphospho-[14C]glucose 
(UDP[14C]G) into glycogen [2,27]. The activity was expressed as a 
ratio of the activity measured in the absence of glucose-6P divided 
by the activity in the presence of this allosteric activator (10 mM). 
Protein was measured according to Bradford [28] using bovine serum 
albumin (Al%/280 nm=6.5) as a standard. 
3. Results 
3.1. Regulation of PKB and GSK3 by insulin in rat skeletal 
muscle in vivo 
Insulin stimulated P K B a activity about 10-fold (Fig. 1A) 
and decreased GSK3 activity by 40% (Fig. IB) in skeletal 
muscle in vivo. As found in other cells, the activation of 
P K B a (data not shown) and the inhibition of G S K 3 (Fig. 
IB) were reversed by incubation with PP2A, a serine/threo-
nine-specific phosphatase. Half-maximal activation of P K B a 
by insulin occurred within 2 min and maximal activation oc-
curred after 5 min (Fig. 1A). Neither the activation of P K B a 
(Fig. 1A) nor the inhibition of G S K 3 (Fig. IB) were prevented 
by rapamycin under conditions where the activation of 
p70 S6 kinase was blocked completely (Fig. 2A). Moreover, 
rapamycin had no effect on the insulin-induced activation of 
glycogen synthase by insulin after 5 min (Fig. 2B), consistent 
with the lack of activation of p70 S6 kinase at this time (Fig. 
2A). However, the small additional activation of glycogen 
synthase by insulin occurring between 5 and 30 min was par-
tially suppressed by rapamycin. Little or no activation of 
M A P K A P - K 1 by insulin was detected under these conditions 
(data not shown). 
3.2. Regulation of PKB, GSK3 and MAP kinase by insulin and 
EGF in primary rat adipocytes 
Insulin stimulated P K B a activity 14-fold (Fig. 3A) and de-
creased GSK3 activity by 60% (Fig. 3B) in adipocytes, and 
these effects were reversed by treatment with PP2A (data not 
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Fig. 1. Activation of PKB and inhibition of GSK3 by insulin in rat 
skeletal muscle in vivo. Skeletal muscles were exposed to rapamycin 
(■, A ) or buffer (□) before stimulation with (□,■) or without ( A ) 
insulin. A: PKBa was immunoprecipitated from the extracts and as-
sayed in triplicate as described under Section 2. PKBa activities are 
presented as a percentage of the maximal specific activity attained 
after stimulation with insulin for 5 min in the absence of rapamycin 
(1.2 mU/mg) and are given ±SEM for three separate experiments. 
B: Skeletal muscles were freeze clamped 10 min after stimulation 
with insulin and both GSK3 isoforms were co-immunoprecipitated 
from the extracts. The immunoprecipitates were incubated without 
or with PP2Ai prior to assay, and GSK3 activity is expressed as a 
reactivation ratio; i.e. GSK3 activity measured without PP2Ai treat-
ment divided by GSK3 activity after PP2Ai treatment. The data are 
presented as the mean ± SEM for the number of different experi-
ments shown in parentheses. 
time (min) 
20 
time (min) 
Fig. 2. Effect of rapamycin on the activation of p70 S6 kinase and 
glycogen synthase by insulin in skeletal muscle in vivo. Skeletal 
muscle in vivo was exposed to rapamycin (■, A ) or buffer (□) and 
then stimulated with (□, ■) or without ( A ) insulin for the times in-
dicated. p70 S6 kinase was immunoprecipitated from the extracts 
and assayed as described under Section 2, while glycogen synthase 
activity was assayed directly in the cell extracts in the absence and 
presence of glucose-6P. p70S6 kinase activities are presented as a 
percentage of the maximal specific activity attained after stimulation 
with insulin for 15 min in the absence of rapamycin (2.2 mU/mg). 
Glycogen synthase activity is presented as an activity ratio—/+glu-
cose-6P. Assays were performed in duplicate and the data are given 
as ± SEM for three separate experiments. 
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Fig. 3. Stimulation of PIP3 and PKB and inhibition of GSK3 in 
primary rat adipocytes. Adipocytes were stimulated with 200 nM in-
sulin (open symbols or bars) or 200 ng/ml EGF (closed symbols or 
bars) for the times indicated and, after cell lysis, PKBa and both 
GSK3 isoforms were immunoprecipitated and assayed as described 
under Section 2. A: PKBa activity is presented as a percentage of 
the maximal activity attained after stimulation for 20 min with insu-
lin (±SEM for three separate experiments). B: GSK3 activity is 
presented as a percentage of the activity measured in extracts from 
unstimulated adipocytes (±SEM for three separate experiments). C: 
The formation of PIP3 was measured in triplicate at each time point 
and the data show the results of at least two independent experi-
ments. 
shown). Half-maximal activation of PKBa and inhibition of 
GSK3 by insulin occurred within 2 min with a maximal effect 
after 5 min and, like the stimulation of glucose uptake and 
glycogen synthesis, the activation of PKBa and inhibition of 
GSK3 by insulin were sustained for at least 1 h. 
In contrast to insulin, EGF induced only a 3-fold activation 
of PKBa, which peaked after 2 min and returned to near 
basal levels after 10-20 min (Fig. 3A). Consistent with this 
finding, EGF induced only a small (20%) inhibition of GSK3 
after 2 min which returned to control levels after 10-20 min 
(Fig. 3B). EGF induced a stronger activation of p42 MAP 
kinase than insulin (data not shown) as reported in [20]. 
3.3. Effect of insulin and EGF on the level of phosphatidyl-
inositide-3,4,5-trisphosphate in primary rat adipocytes 
The insulin and EGF induced activation of PKBa and the 
insulin induced inhibition of GSK3 in adipocytes were unaf-
fected by rapamycin but prevented by wortmannin (data not 
shown), indicating that, as in other cells, the regulation of 
these enzymes by insulin is mediated by the activation of 
PI 3-kinase. Consistent with the kinetics of activation of 
PKBa and inhibition of GSK3, insulin induced a greater 
than 10-fold increase in the level of phosphatidylinositol-
3,4,5-trisphosphate (PIP3), the product of the PI 3-kinase 
reaction, which peaked within 1 min and was sustained for 
1 h (Fig. 3C). In contrast, EGF induced a 3^1-fold activation 
of PIP3 which also peaked within 1 min but declined to near 
control levels after 6 min (Fig. 3C). 
4. Discussion 
To our knowledge, this is the first report that insulin acti-
vates PKB in the major insulin-responsive tissues of the body 
(skeletal muscle and adipocytes), and that the rate (half-time: 
1-2 min) and extent ( > 10-fold) of activation (Fig. 1 AFig. 
3A) are similar to those observed in mammalian cell lines 
[10,16,17]. We also establish that insulin inhibits GSK3 in 
skeletal muscle in vivo by inducing its phosphorylation at a 
serine/threonine residue(s) (Fig. IB). Moreover, the rate of 
inhibition of GSK3 in skeletal muscle and adipocytes is con-
sistent with it lying downstream of PKB and upstream of 
glycogen synthase in the signal transduction pathway by 
which insulin activates glycogen synthase. 
A strong correlation between the extent and duration of 
activation of PKBa and the extent and duration of inhibition 
of GSK3 also emerged when the effects of insulin were com-
pared to those of EGF in adipocytes. Whereas insulin induced 
a greater than 10-fold activation of PKBa that was sustained 
for at least 1 h, EGF only induced a 3-fold activation of 
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PKBa which peaked after 2 min and returned to near basal 
levels after 10-20 min (Fig. 3A). This may explain why insulin 
induced a 60% decrease in GSK3 activity in adipocytes that 
was sustained for at least 1 h, whereas EGF only induced a 
maximum 20% decrease in GSK3 activity after 2 min which 
returned to control levels after 10-20 min. The stimulation of 
glucose transport and activation of glycogen synthase by in-
sulin is also sustained for at least 1 h [20], and the small and 
very transient rise in PIP3 (Fig. 3C) and PKBa (Fig. 3A) and 
decrease in GSK3 activity (Fig. 3B) may explain why, in con-
trast to insulin, EGF fails to stimulate glucose transport and 
glycogen synthesis significantly in adipocytes. This would be 
analogous to the situation in pheochromocytoma (PC 12) cells 
where NGF induces neuronal differentiation by triggering a 
sustained activation of the MAP kinase cascade, whereas 
EGF [29] and insulin [30] do not because the activation of 
MAP kinase by these agonists is too transient. The transient 
activation of PKB may also underlie the failure of platelet-
derived growth factor (PDGF) to stimulate glucose transport 
in 3T3-L1 adipocytes [31], without the need to invoke more 
complex mechanisms such as the specific targetting of acti-
vated PI 3-kinase to GLUT-4 vesicles [31]. In primary adipo-
cytes we failed to observe any effect of PDGF on the level of 
PIP3, or on the activities of PKBa and p42 MAP kinase (J. 
van der Kaay and M. Shaw and unpublished work), presum-
ably because these cells lack PDGF receptors. 
Rapamycin had no effect on the activation of PKBa (Fig. 
1A) or on the inhibition of GSK3 (Fig. IB) by insulin in 
skeletal muscle, or on the inhibition of GSK3, the activation 
of glycogen synthase or the stimulation of glycogen synthesis 
by insulin in primary adipocytes [14,20]. We also failed to find 
any effect of rapamycin on the activation of glycogen synthase 
in skeletal muscle up to 5 min after stimulation by insulin 
(Fig. 2B), a time point at which the increase in glycogen 
synthase activity had reached 70% of its maximal level. These 
findings were consistent with the observation that p70 S6 
kinase, an enzyme whose activation is prevented by rapamy-
cin, was not stimulated by insulin after 5 min but only at later 
times (Fig. 2A). Consistent with this finding, Chang et al. [18] 
have reported that rapamycin does not inhibit the activation 
of glycogen synthase in normal mouse skeletal muscle 20 min 
after an intravenous injection of insulin. We therefore con-
clude that rapamycin-insensitive pathways are mainly respon-
sible for mediating the acute inhibition of GSK3 and activa-
tion of glycogen synthase in the major insulin-responsive 
tissues of the body. 
Rapamycin has been reported to suppress the activation of 
glycogen synthase and glycogen synthesis by insulin in 3T3-L1 
adipocytes [21] and incubated rat hemidiaphragm [22]. How-
ever, as found in primary adipocytes (Fig. 3) and in rat skel-
etal muscle in vivo (Fig. 1), the insulin-induced activation of 
PKBa and the inhibition of GSK3 are unaffected by rapamy-
cin in the incubated rat hemidiaphragm (D. Cross and K. 
Walker, unpublished work) raising the question of how rapa-
mycin inhibits the activation of glycogen synthase by insulin 
in 3T3-L1 adipocytes and hemidiaphragms, and in rat skeletal 
muscle after 5 min (Fig. 2B). One of many possible explan-
ations is that P P I . G M activity (see Section 1) is stimulated by 
a rapamycin-sensitive kinase, and that the relative contribu-
tions made by the inhibition of GSK3 and the activation of 
P P I G M to the activation of glycogen synthase by insulin vary 
from tissue to tissue. However, p70 S6 kinase is unlikely to 
be the protein kinase which activates PP1 .GM in vivo because 
it does not phosphorylate the GM subunit in vitro [32]. More 
detailed analysis of the effect of insulin on the phosphoryla-
tion of GM in vivo will be needed to resolve this problem. 
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